The Prostate 67:1576 ^1589 (2007)
Epigallocatechin-3 -Gallate Suppresses Early Stage, but
not Late Stage Prostate Cancer inTRAMP Mice:
Mechanisms of Action
Curt E. Harper,1 Brijesh B. Patel,1 Jun Wang,1 Isam A. Eltoum,2,3
and Coral A. Lamartiniere1,2*
1
Department of Pharmacologyand Toxicology,University of Alabama at Birmingham, Birmingham, Alabama
2
UAB Comprehensive Cancer Center,University of Alabama at Birmingham, Birmingham, Alabama
3
Department of Pathology,University of Alabama at Birmingham, Birmingham, Alabama
BACKGROUND. Prostate cancer (PCa) is the second leading cause of cancer-related death in
men in the United States. Many men have implemented purported chemopreventive agents into
their daily diet in an attempt to delay the early onset of a PCa. Green tea polyphenols, one such
agent, has been shown to be chemopreventive in skin, breast, and prostate cancers. We
hypothesized that Epigallocatechin-3-Gallate (EGCG), the major polyphenol found in green tea,
will exert its chemopreventive effect in the prostate via regulation of sex steroid receptor,
growth factor-signaling, and inflammatory pathways.
METHODS. Five-week-old male TRAMP (Transgenic Adenocarcinoma Mouse Prostate)
offspring were fed AIN-76A diet and 0.06% EGCG in tap water. Animals were sacrificed at
28 weeks of age and the entire prostates were scored histopathologically. In addition, animals
were sacrificed at 12 weeks of age and ventral (VP) and dorsolateral (DLP) prostates were
removed for histopathological evaluation and immunoblot analyses or ELISA.
RESULTS. EGCG, inhibited early but not late stage PCa in the current study. In the VP, EGCG
significantly reduced cell proliferation, induced apoptosis, and decreased androgen receptor
(AR), insulin-like growth factor-1 (IGF-1), IGF-1 receptor (IGF-1R), phospho-extracellular
signal-regulated kinases 1 and 2 (phospho-ERKs 1 and 2), cyclooxygenase-2 (COX-2), and
inducible nitric oxide synthase (iNOS).
CONCLUSIONS. The attenuation of the AR, the down-regulation of potent growth factor IGF1, modulation of inflammation biomarkers, and decrease in the MAPK signaling may contribute
to the reduction in cell proliferation and induction of apoptosis and hence provide a biochemical
basis for EGCG suppressing PCa without toxicity. Prostate 67: 1576–1589, 2007.
# 2007 Wiley-Liss, Inc.
KEY WORDS:
EGCG; TRAMP; AR; IGF-1; prostate cancer; chemoprevention
INTRODUCTION
Prostate cancer (PCa) is a disease that is responsible
for approximately 40,000 deaths per year and is
the second-leading cause of cancer-related death
among men in the United States [1]. PCa starts to
develop early in life with pre-neoplastic lesions
appearing as early as 40–50 years of age in men [2,3].
High-grade prostatic intraepithelial neoplasia (HGPIN) is considered the precursor to prostate adenocarcinoma [4]. HG-PIN has a high predictive value as a
ß 2007 Wiley-Liss, Inc.
Grant sponsor: Department of Defense; Grant number: DAMD PC
17-03-1-0153; Grant sponsor: National Cancer Institute Cancer
Prevention and Control Training Program NCI; Grant number: CA
47888.
*Correspondence to: Coral A. Lamartiniere, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670
University Blvd., Volker Hall 124, Birmingham, AL 35294-0019.
E-mail: Coral@ uab.edu
Received 1 May 2007; Accepted 3 July 2007
DOI 10.1002/pros.20643
Published online 17 August 2007 in Wiley InterScience
(www.interscience.wiley.com).
EGCG Suppresses HG-PIN
marker for prostate adenocarcinoma, and its identification warrants biopsy for invasive carcinoma.
Green tea polyphenols (GTPs) have been shown to
be effective in preventing pre-malignant lesions before
PCa develops in humans [5]. In addition, Gupta et al.
and others have demonstrated the ability of green tea
polyphenols (GTPs) to suppress PCa in the Transgenic
Adenocarcinoma Mouse Prostate (TRAMP) model [6–8].
Studies have linked the low incidence of PCa in Chinese
populations to the consumption of green tea. [9,10].
However, other studies have failed to find an association between green tea consumption and the risk of
PCa [11,12]. Despite opposing epidemiological data,
many men have implemented purported chemopreventive agents, such as green tea extracts, into their
daily diet in an effort to delay the progression of PCa.
Green tea is comprised of a number of polyphenolic
compounds known as catechins including epigallocatechin-3-gallate (EGCG), epicatechin (EC), epigallocatechin (EGC), and epicatechin-3-gallate (ECG). EGCG, the
most abundant GTP in green tea, accounts for 50–80% of
the tea catechins. Furthermore, EGCG has been credited
with many of the health benefits of green tea. Yet, it
remains unclear whether these benefits are due to EGCG
alone or if an additive or synergistic effect exists in green
tea due to the combination of GTPs. Studies using GTPs
in PCa have focused on an array of signaling pathways
responsible for maintaining a balance between proliferation and apoptosis. The insulin-like growth factor-1
(IGF-1) ligand, and its corresponding binding proteins
and receptor are important in normal prostate growth
and development as well as PCa initiation and progression. The IGF-1 signaling pathway can activate the
Ras/MAPK and PI3K/Akt pathways. High circulating
levels of IGF-1 in the blood have been associated with an
increased risk of PCa in humans [13,14]. In the TRAMP
model, Adhami et al. [15] showed a decrease in IGF-1
and an increase in IGF-binding protein 3 (IGF-BP3)
levels in the blood serum of GTP-treated animals. In
addition, phospho-extracellular signal-regulated kinases 1 and 2 (phospho-ERKs 1 and 2), components of the
MAPK pathway responsible for cell proliferation, differentiation, and death, were down-regulated by GTP in
TRAMP mice [15].
In comparison, ECGG as a single agent can modulate
the production and biological actions of androgens and
other hormones [16]. The androgen receptor (AR) plays
a dominate role in the molecular endocrinology of PCa.
AR participates in tumor progression by activating
and/or up-regulating receptor activity, point mutations, and ligand-independent activation by growth
factor signaling pathways (i.e., IGF-1) [17]. Using
LNCaP cells PCa cells, Ren et al. [18] described the
down-regulation of the AR expression with EGCG.
Evidence shows that 85 mg EGCG/kg BW can regulate
The Prostate DOI 10.1002/pros
1577
the endocrine system by lowering testosterone and
estradiol concentrations in the blood serum of male
Zuker rats [19]. EGCG also modulates inflammation by
inhibiting MMP-2 activation [20] in TRAMP-C1 cells
and acts as an anti-oxidant by alleviating oxidative and
nitrosative injuries in TRAMP mice [21].
It is of fundamental importance to determine if the
biological responses caused by green tea are caused
solely by EGCG prior to utilizing EGCG as a single
agent in clinical trials or taking EGCG supplements. In
the current study, we investigated the potential of
EGCG, as a single agent, to protect against the
progression of PCa using the TRAMP model, an animal
that closely mimics PCa in humans [22]. In the TRAMP
model, Simian Virus-40 T-antigen (SV-40 Tag) is under
direct transcriptional control of the probasin promoter
allowing androgen-regulated protein expression specific to the prostate epithelium. The TRAMP model
created in 1996 by Greenberg et al. [22] has been used
extensively over the past decade in PCa chemoprevention studies [6,23–27]. For this study, we hypothesized
that dietary EGCG would protect against HG-PIN, the
precursor to PCa, and spontaneously developing
prostate adenocarcinoma by regulating sex steroid
receptor, IGF-1 signaling, and COX-2 and iNOS in the
prostate.
MATERIALS AND METHODS
Animals and Treatments
Animal care and use were conducted according to
established guidelines approved by the National
Institutes of Health (NIH) and the Institutional Animal
Care and Use Committee (IACUC) at the University of
Alabama at Birmingham (UAB). Breeders were purchased from the NCI Mouse Repository (Cancer
Research Center, Frederick, MD) and used to develop
our colony. Heterozygous transgenic (SV-40 Tag)
females were crossed with non-transgenic C57BL/
6 males to generate heterozygous transgenic (SV-40
Tag) male offspring for our studies (TRAMP C57BL/
6 females X C57BL/6 male breeders). Mice were
housed in rooms maintained at 24 1C with a 12 hr
light-dark cycle. At 3 weeks of age, offspring were tailclipped and weaned. Mouse-tail DNA was extracted
using a DNeasy Tissue Kit (Qiagen, Valencia, CA) and
PCR was performed to determine the presence of the
SV-40 Tag transgene [22,25].
Twelve weeks of age was selected to evaluate the
influence of EGCG on early-stage PCa, specifically the
transition from HG-PIN to well-differentiated carcinoma. Twelve weeks of age, a time point prior to
heterogeneous tumor formation, is ideal for investigating the mechanisms of action in the TRAMP model. At
1578
Harper et al.
12 weeks of age, TRAMP mice display pre-malignant
lesions but have not developed tumors that have the
capacity to compromise oxygen and nutrients to the
tissue. To investigate the effects of EGCG on apoptosis,
cell proliferation, and protein biomarkers, animals were
killed at 12 weeks of age and dorsolateral (DLP) and
ventral prostates (VP) were excised, collected, weighed,
flash-frozen in liquid nitrogen, and stored at 80C
until time of analysis. Since it is unclear which lobe in the
rodent resembles the human peripheral zone, the
prostatic location in humans where PCa normally occurs
[28], we chose to analyze both the DLP, which has
historically been referred to as the homologue of the
human prostate and the VP for mechanism of action
studies. Based on our previous studies, 28 weeks of age
was selected to evaluate the ability of EGCG to prevent
late-stage poorly differentiated PCa. At that age mice
were not set up for mechanistic studies since a large
percentage of these animals develop macroscopic
tumors in the prostate and the separation of lobes is
not possible. Blood serum was collected at both 12 and
28 weeks of age.
Dietary treatment with EGCG was initiated at
5 weeks of age and continued until sacrifice at 12 or
28 weeks of age. Animals received powdered phytoestrogen-free AIN-76A diet (Harlan Teklad Global Diets,
Wilmington, DE) and tap water (control) or 0.06%
EGCG (treatment) ad libitum. The EGCG dose was
extrapolated from the PCa chemoprevention study
carried out by Gupta et al. that used 0.1% GTPs of which
62% of those green tea catechins were EGCG [6]. EGCG
was prepared and administered fresh daily and the
feeding regimen mimics an approximate human consumption of six cups of green tea [29]. Food and water
consumption, as well as body weights were monitored
at 6, 12, 18, 24, and 28 weeks of age. Tumor palpation
was initiated at 18 weeks of age, initially once per week,
and then twice per week starting at 24 weeks of age
until sacrifice.
Chemicals
EGCG (Roche, Basel, Switzerland), extracted from
non-fermented Camellia sinensis and tested as 93% pure by
HPLC, was mixed at 0.06% in tap water. Amber-colored
bottles were used to prevent oxidation caused by light.
Histopathology
At necropsy, all organs were examined for gross
abnormalities in control and EGCG-treated animals.
Metastasis to the bone, abdominal wall, lymph nodes,
liver, kidney, and lung was investigated. Prostate,
testes, seminal vesicles, and if present, tumor weights
were also recorded. The entire urogenital tract containing the DLP, VP, and urethra were placed in cassettes,
The Prostate DOI 10.1002/pros
immersed in 10% formalin, dehydrated in a series of
alcohol dilutions, fixed in xylene, embedded in paraffin
wax, sliced into 5 mm sections, and placed on microscope slides as described by Folkvord et al. [30].
Sections were stained with hematoxylin and eosin
prior to histopathological examination. Dr. Isam
Eltoum, a Board Certified Pathologist, blindly scored
each coded sample using the following grading scale
developed specifically for rodents: Grade 1 (noncancerous), Grade 2 (low-grade PIN), Grade 3 (HGPIN), Grade 4 (well-differentiated lesion), Grade 5
(moderately differentiated lesion), or Grade 6 (poorly
differentiated lesion) [24,25].
Cell Proliferation
Prostate tissue (DLP and VP) were dissected from
12-week-old TRAMP mice (6 controls, 6 EGCG-treated)
and processed for detecting Ki-67, a marker of cell
proliferation. Briefly, paraffin-embedded tissue sections (5 mm) on glass slides were deparaffinized in
xylene and rehydrated in a gradient of alcohols.
Samples were boiled in Antigen Unmasking Solution
(Vector, Burlingame, CA) for 15 min and then cooled
under tap water. H2O2 (3%) was used to inhibit
endogenous peroxidase activity by incubation at room
temperature for 10 min. Blocking was accomplished
using 2.5% Normal Horse Serum from the
ImmPRESSTM Reagent Kit (Anti-Mouse Ig) (Vector).
Next, monoclonal mouse anti-rat Ki-67 antigen, Clone
MIB-5 antibody (DakoCytomation, Carpinteria, CA)
diluted in PBS with 1% BSA was applied overnight
to the specimens and followed by washes in PBS.
ImmPRESSTM Reagent secondary antibody was
applied to the samples for 30 min followed by washes
in PBS. Chromogen, diaminobenzidine (DAB) (Vector)
was applied to samples for 10 min followed by a wash
in tap H2O for 5 min. To counterstain, hematoxylin QS
(Vector) was applied to the specimens for 1 min,
followed by a wash in tap H2O. Specimens were
immersed in a series of graded alcohols, placed in
xylene, and mounted with coverslips using Mounting
Media (Vector). The slides were viewed using a Nikon
Labophot-2 microscope (Nikon Corporation, Tokyo,
Japan) and digitally recorded using a Nikon 8.0 Mega
Pixels CoolPix 8700 Digital Camera (Nikon). For Ki67
quantitation, epithelial cells were counted using Image
J software (Image J, NIH). The DLP and VP were
analyzed separately (a minimum of 2,000 cells counted
per lobe per slide; six samples each). The epithelial cells
staining positive (brown) for Ki67 were counted as well
as the non-proliferative epithelial cells (stained blue).
The proliferative index was defined as the number of
positively stained cells divided by the total number of
cells counted X 100. Twenty eight-week-old TRAMP
EGCG Suppresses HG-PIN
prostate tumor with and without Ki67 primary antibody was used as positive and negative controls,
respectively.
Apoptosis
Apoptotic bodies were counted from tissue sectionedslides stained with hematoxylin and eosin to assess
apoptotic index in 12-week-old control or EGCGtreated TRAMP mice (6 each). The morphological
criteria for identifying apoptosis were based on
previously published studies [31–33]. Briefly, apoptotic bodies consist of rounded masses of cytoplasm
containing hyperchromatic pyknotic nuclei, dense
chromatin fragments, and/or cellular fragments.
Apoptotic bodies are usually surrounded by a clear
halo. Only structures with unequivocal features of
apoptosis were counted. Each slide was evaluated
using a Nikon Labophot-2 light microscope (Nikon),
digitally recorded using a Nikon 8.0 Mega Pixels
CoolPix 8700 Digital Camera (Nikon), and counted
using Image J software acquired from the National
Institute of Health (NIH). The DLP and VP were
analyzed separately by counting at least 2,000 cells per
prostate lobe. The epithelial cells displaying apoptotic
bodies were counted as well as the non-apoptotic
epithelial cells. An apoptotic index was defined as
the number of apoptotic bodies divided by the total
number of cells counted X 100.
SV- 40 Tag
Immunohistochemistry (IHC) was employed to
measure SV-40 Tag expression in the DLP and VP of
12-week-old control (n ¼ 6) and EGCG-treated (n ¼ 6)
TRAMP mice. SV-40 Tag expression was semi-quantitated and localization was evaluated as described
previously [34]. SV-40 Tag was measured to determine
if the effects of EGCG was due to a direct biological
effect on the prostate or an indirect effect caused by an
alteration in transgene expression. Non-transgenic
C57/BL6 mouse prostate and rat mammary gland
were used as negative controls.
Immunoblot Analyses
The protein expression levels of biomarkers were
measured by western blot analysis as described
previously [35]. The following primary antibodies
were purchased from commercial sources: AR (Santa
Cruz Biotechnology, Santa Cruz, CA, SC-816), ER-a
(Santa Cruz, SC-542), insulin-like growth factor-1
receptor (IGF-1R) (Santa Cruz, SC-712), insulin-like
growth factor-binding protein 3 (IGF-BP3) (Santa Cruz,
SC-9028), phospho-ERKs 1 and 2 (Cell Signaling
Technology, Danvers, MA, #9101S), total-extracellular
The Prostate DOI 10.1002/pros
1579
signal-regulated kinases 1 and 2 (total-ERKs 1 and 2)
(Cell Signaling, #9102), cyclooxygenase-2 (COX-2)
(Santa Cruz, SC-1745), and inducible nitric oxide
synthase (iNOS) (Santa Cruz, SC-651). SuperSignal
West Dura Chemiluminescence (Pierce, Rockford, IL)
was applied to detect the proteins of interest. The
relative intensity of the bands was measured using
VersaDoc Imaging System (BioRad, Hercules, CA). The
use of Kaleidoscope Precision Plus Protein and Prestained SDS–PAGE Broad Range standards (BioRad)
as well as positive controls aided in correctly identifying the proteins of interest.
Enzyme Linked Immunosorbent Assay (ELISA)
We quantitated IGF-1 levels in the prostate by ELISA
as described by Crowther et al. [36]. Prior to analysis,
kinetic curves were set up to establish zero order
kinetics. For each sample, 1 mg of protein was diluted in
100 ml of coating solution (10 mM PBS, pH 7.2) and
applied to a 96-well Nunc-Immuno plate (Nage Nunc
International, Rochester, NY). Next, overnight incubation at room temperature and a series of washes with
1 PBS þ 0.05% Tween-20 (BioRad) were implemented. To block extraneous binding sites, PBS þ 1%
BSA was applied for 1 hr and then washed. Rabbit
polyclonal IGF-1 primary antibody (Santa Cruz, SC9013) diluted in 10 mM PBS þ 1% BSA was added and
incubated for 2 hr. After washing with PBS, HRPconjugated anti-rabbit secondary antibody diluted in
PBS þ 1% BSA was incubated for 4 hr at room temperature. Following a series of washes, the reaction was
incubated with the ImmunoPure TMB Substrate Kit
(Pierce) and stopped using 2N H2SO4. Samples were
run in duplicate and the absorbance at 450 nm was read
in an OPTI max Microplate reader (Molecular Devices,
Sunnyvale, CA). Mouse liver with and without IGF-1
primary antibody was used as a positive and negative
control, respectively.
Blood Serum Hormone Concentrations
Serum total testosterone (bound and unbound),
dihydrotestosterone (DHT), and estradiol concentrations were measured in the blood serum of 12- and
28-week-old control and EGCG-treated transgenic
animals using radio-immunoassays (Diagnostic Systems Laboratories, Webster, TX) as described by the
manufacturer. All samples were run in duplicate with
8 samples per group by Dr. John Mahan (OB/GYN
Department, UAB, Birmingham, AL).
Polyphenol Concentrations in Blood Serum
Whole blood was collected from 12-week-old mice
at time of sacrifice and centrifuged at 2,300 rpm for
1580
Harper et al.
10 min to collect serum. EGCG was extracted from the
serum and measured on a 4000 Q TRAP1 LC/MS/MS
System (Applied Biosystems, Foster City, CA). Serum
extractions were carried out as described previously
[37,38]. Apiginin, 4-methylumbelliferone, and phenolphthalein glucuronide were added as internal
standards. For EGCG serum analysis, 1% acetic acid
in 100% methanol was used after incubation with
internal standards and b-glucuronidase enzyme. Samples were reconstituted in 80% methanol prior to LC/
MS/MS injection. Control serum from animals exposed
to AIN-76A diet and tap water only was used as
negative controls. Values were reported in molarity
(nM).
Statistics
Fisher’s exact test was used to evaluate histopathological grade frequencies among treatment groups.
Statistical comparisons were performed using twosample Student t-test assuming unequal variances for
western blot analysis and ELISA. P < 0.05 was considered to be significant.
RESULTS
EGCG in the Diet Suppresses Early Stage
PCa inTRAMP Mice
At 12 weeks of age, dietary EGCG significantly
reduced the incidence of HG-PIN (Grade 3) from 100%
to 17% in the VP of TRAMP mice (Table I). The
suppression of HG-PIN (Grade 3), the precursor to
prostate adenocarcinoma, was accompanied by a delay
in progression of low-grade PIN (Grade 2) from 0% in
controls to 83% in EGCG-treated animals. In the DLP of
12-week-old transgenic mice, EGCG did not have a
protective effect. At 28 weeks of age, 67% of the TRAMP
mice had carcinomas (Grades 4–6), including 23%
having poorly differentiated tumors (Grade 6), there-
fore making it difficult to evaluate the VP from the DLP
(Table II). Therefore, the complete urogenital tract/
tumor was evaluated as one entity. At this age
(28 weeks), there was no significant effect on all
pathological stages from EGCG treatment. There was
no statistical change in latency, number of palpable
tumors per animal, tumor weight, or number of liver,
kidney, lung, or lymph node metastases between the
control- and EGCG-treated animals.
Transgene Expression was not Altered
by EGCG Treatment
At 12 weeks, SV-40 Tag protein expression was
investigated to determine if the effect of EGCG on
histopathology and biomarkers was due to regulation
of the probasin promoter. There was no EGCG treatment effect on SV-40 Tag expression in the DLP and VP
epithelia (Fig. 1A–D).
Dietary EGCG Inhibits Epithelial Cell
Proliferation and Increases Apoptosis
in the Prostates of TRAMP Mice
To investigate the mechanisms of action of EGCG in
preventing HG-PIN, we chose 12 weeks as the age to
investigate since this is the age at which 100% of the
untreated transgenic mice developed HG-PIN. As
demonstrated by the Ki67 assay, cell proliferation was
similar in VP and DLP of control-treated mice, with
proliferative indices of 13 and 14 respectively (Fig. 2A–
E). EGCG significantly decreased epithelial cell proliferation by 54% in the VP. There was change in cell
proliferation in the DLP from EGCG treatment
(Fig. 2A–E). The apoptotic index was twice as high in
the DLP as in the VP of control-treated animals (Fig. 2F).
Analysis of apoptosis showed that controlled cell death
was significantly increased in the VP (fivefold; 394%),
but not in the DLP (Fig. 2F).
TABLE I. Histopathological Analysis of the DLP and VP of 12-Week-Old TRAMP Mice Fed AIN-76A Diet and Tap Water
(Control) or 0.06% EGCG inTap Water Starting at 5 Weeks of Age
Grade level
Treatment
n
Lobe
1 (%)
2 (%)
3 (%)
4 (%)
5 (%)
6 (%)
Control
EGCG
Control
EGCG
6
6
6
6
VP
VP
DLP
DLP
0
0
0
0
0
83*
0
0
100
17*
100
100
0
0
0
0
0
0
0
0
0
0
0
0
Samples were given a score of (1) normal tissue, (2) low-grade PIN, (3) high-grade PIN, (4) well-differentiated tumor, (5) moderately
differentiated tumor, and (6) poorly differentiated tumor depending on the presence and progression of lesions. Results are the
percentage of mice as a function of the pathological score.
*P < 0.05 compared to control treatment.
The Prostate DOI 10.1002/pros
EGCG Suppresses HG-PIN
1581
TABLE II. Histopathological Analysis of the Urogenital Tract of 28 -week-old TRAMP
Mice Fed AIN-76A Diet and Tap Water (Control) or 0.06% EGCG inTap Water Starting at
5 Weeks of Age
Grade level
Treatment
n
1 (%)
2 (%)
3 (%)
4 (%)
5 (%)
6 (%)
Control
EGCG
53
25
0
0
0
0
34
32
42
44
2
4
23
20
Samples were given a score of (1) normal tissue, (2) low-grade PIN, (3) high-grade PIN, (4) welldifferentiated tumor, (5) moderately differentiated tumor, and (6) poorly differentiated tumor
depending on the presence and progression of lesions. Results are the percentage of mice as a
function of the pathological score.
AR, but not ER-a is Differentially Regulated
in EGCG-Treated TRAMP Mice
Since early stage PCa is usually considered androgen dependent, we measured AR by western blot
analysis. In the VP, AR protein expression was
significantly reduced by 51% (Fig. 3), but there was no
difference in AR in the DLP from EGCG treatment.
EGCG in the water did not alter ER-a in either the VP or
DLP (Fig. 3). Measurement of sex steroid hormones in
blood serum showed that testosterone, estradiol, and
DHT concentrations were not significantly different
between control- or EGCG-treated mice at 12- and 28week of age (data not shown).
IGF-1Signaling Proteins Are Differentially
Regulated in the Prostates of TRAMP
Mice Following EGCG Treatment
Dietary EGCG significantly reduced IGF-1 protein
levels in the VP by 30% and in the DLP by 31% (Fig. 4).
In contrast, IGF-1R protein expression was significantly
down-regulated (42%) in the VP, but remained
unchanged in the DLP (Fig. 4). The protein expression
of IGF-BP3, the most abundant IGF-1 binding protein,
was not significantly different in the VP or DLP (data
not shown). In addition, we investigated the effect of
EGCG on specific protein expressions in the liver,
the major site of IGF-1 production. IGF-1, IGF-1R, and
Fig. 1. Immunohistochemical staining of SV- 40 Tag (40 magnification) in theVP (A,B) and DLP (C,D) of12-week-old TRAMP mice fed AIN76A diet and tapwater (Control) or 0.06% EGCGin tapwater starting at 5 weeks of age. Arrows exemplify (brown) positiveprostatic epithelial
cells expressingSV- 40Tag(transgenemarker).[Color figure canbeviewedinthe onlineissue,whichisavailableatwww.interscience.wiley.com.]
The Prostate DOI 10.1002/pros
Fig. 2. Cellproliferationandapoptosis.ImmunohistochemicalstainingofKi- 67(40 magnification)intheVP(A,B)andDLP(C,D)of12-weekoldTRAMPmicefedAIN-76Adietandtapwater(Control)or0.06%EGCGintapwater startingat5weeksofage.Arrows show(brown)positive
prostatic epithelial cells expressing Ki- 67 (cell proliferation marker).E: Data represent the cell proliferative indices and (F) apoptotic indices.
*P < 0.05 compared to control treatment. [Color figure canbeviewedin the onlineissue, whichis available at www.interscience.wiley.com.]
The Prostate DOI 10.1002/pros
EGCG Suppresses HG-PIN
1583
Fig. 3. AR and ER-a proteinexpressioninVP and DLPof12-week-old TRAMP mice fed AIN-76Adiet and tapwater (Control) or 0.06% EGCG
in tap water starting at 5 weeks of age. Upper bands depict western blots for AR and ER-a and the lower figure is a graph of densitometry
measurements from these western blot analyses. Each sample consisted of three pooled prostates and each group contained eight samples.
Densitometry values for controlmicewere set at100. **P < 0.001compared to control treatment.
IGF-BP3 protein expressions did not differ in the liver
between control- and EGCG-treated mice (data not
shown).
EGCG Down-Regulates Phospho-ERKs1
and 2 Protein Expressions in theVentral
Prostates of TRAMP Mice
Protein tyrosine kinases, ERK-1 (p44 MAPK) and
ERK-2 (p42 MAPK) are downstream effectors of the
IGF-1 signaling pathway and when activated can lead
to cell proliferation. Phospho-ERKs 1 and 2 (activated
forms) protein expressions in the VP were decreased by
45% and 57%, respectively (Fig. 5). On the other hand,
EGCG did not alter phospho-ERKs 1 and 2 protein
expressions in the DLP (Fig. 5). Total-ERKs 1 and 2
(phosphorylated and unphosphorylated) remained
unchanged in DLP and VP (data not shown).
The Prostate DOI 10.1002/pros
EGCG Reduced Both COX-2 and iNOS Protein
Expression in theVentral Prostate
We investigated COX-2 and iNOS, enzymes that
mediate inflammatory processes and are associated
with carcinogenesis, by western blot analysis. COX-2
and iNOS were found to be significantly decreased
(24% and 77%, respectively) in the VP of EGCG-treated
mice (Fig. 6). Again, following the same pattern as seen
in sex steroid receptor and growth-factor signaling
proteins, COX-2 and iNOS were not altered in the DLP
of EGCG-treated animals when compared to control
(Fig. 6).
EGCG inTapWater is Well-Tolerated but Only Reaches
Low Nanomolar Concentrations in the Blood Serum
EGCG at 0.06% in the drinking water did not show
evidence of toxicity. There was no significant difference
1584
Harper et al.
Fig. 4. IGF-1and IGF-1R protein expressions inVP and DLP of12-week-old TRAMP mice fed AIN-76A diet and tap water (Control) or 0.06%
EGCGin tapwater starting at 5 weeks of age.IGF-1protein expressionwas determined via ELISA.Upper bands depict westernblots for IGF-1R
andthelower figureisagraphofdensitometrymeasurementsfromthesewesternblotanalyses.Eachsampleconsistedof threepooledprostates
and each group containedeight samples.Densitometry values for controlmicewere set at100. **P < 0.01compared to control treatment.
in food or water intake in EGCG-treated mice when
compared to controls. Likewise, EGCG was welltolerated and there was no significant change in the
body weights of EGCG-treated mice compared to
controls at 6, 12, 18, 24, and 28 weeks of age (data not
shown). At 12 weeks of age, there was no significant
change in testes, DLP, VP, or seminal vesicle weights
(data not shown). Prostate to body weight and testes to
body weight ratios did not differ between EGCG and
control-treated mice (data not shown). EGCG (0.06%)
in tap water had low bioavailability and subsequently
reached a steady state concentration of 22 4 nM in the
blood serum (data not shown).
DISCUSSION
Our lab has previously demonstrated that genistein
[25,39], the most abundant polyphenol in soy, and
trans-resveratrol (Harper, unpublished work), an
active phytochemical component in red wine, can
suppress PCa development in the TRAMP model as
single dietary agents. Previously, Gupta et al. reported
that 0.1% GTP could reduce palpable prostate tumors
in 32-week-old TRAMP mice [6]. Histological changes
The Prostate DOI 10.1002/pros
were noted between control- and GTP-treated animals,
but tumors were not scored by a pathologist. Since
EGCG comprised 62% of the before-mentioned preparation, we provided 0.06% EGCG in tap water to our
TRAMP mice to determine if the effects of GTP could be
solely attributed to EGCG. Using this concentration, we
found that EGCG suppressed HG-PIN in the VP, but
not in the DLP, hence demonstrating lobe specificity. In
the TRAMP model, HG-PIN starts to develop by
10 weeks of age, followed by invasive PCa at 18 weeks
of age. Therefore, HG-PIN offers promise as an
intermediate endpoint in PCa chemoprevention studies. The suppression of HG-PIN, the precursor to PCa,
suggests that EGCG alone can act to slow the
progression of PCa. However, we found that the EGCG
treatment did not suppress PCa development in 28week-old TRAMP mice when the entire prostate was
evaluated histopathologically.
Our report reveals several interesting points. First,
EGCG alone may not be responsible for GTP suppressing late stage prostate cancer in the TRAMP model. It is
possible that it is another component of GTP or the
multiple polyphenols in the green tea extract that act
additively or synergistically to have a chemopreventive
EGCG Suppresses HG-PIN
1585
Fig. 5. Phospho-ERKs1and 2 protein expression inVP and DLP of12-week-old TRAMP mice fed AIN-76A diet and tap water (Control) or
0.06% EGCGin tapwater starting at 5 weeks of age.Upper bands depict westernblots for Phospho-ERKS1and 2 and thelower figureis a graph
of densitometry measurements from these western blot analyses.Each sample consisted of three pooled prostates and each group contained
eight samples.Densitometry values for controlmicewere set at100. **P < 0.01and ***P < 0.001compared to control treatment.
effect. Also, it is possible that the mixture of polyphenols in green tea may aid in stabilizing EGCG and
slow its rapid metabolism. Other contributing factors to
the differences seen between studies may include the
use of different background strains [C57BL/6 and FVB]
to generate the TRAMP colony and the low bioavailability of EGCG as a single agent. The nanomolar blood
serum concentrations observed in our study is consistent with those concentrations found in other studies
using 0.06% EGCG [40] and 0.1–0.6% GTPs [41].
Likewise, it has been shown that the pure EGCG has
lower absorption and plasma levels and a higher
excretion rate when given alone than when given in
combination with other GTPs at the same concentration
[42].
In reference to lobe specificity, that may explain why
we do not see a suppression of prostate cancer at
28 weeks, that is, EGCG is effective only in suppressing
prostate cancer development in the VP and not the DLP
The Prostate DOI 10.1002/pros
and by 28 weeks prostate cancer progression in the DLP
has overwhelmed the VP. This is supported by the fact
that we were no longer able to dissect the individual
lobes at that age. EGCG molecular mechanisms of
action support the latter.
Consistent with EGCG suppressing high grade PIN
in TRAMP mice, EGCG decreased epithelial cell
proliferation and increased apoptosis in the VP at
12 weeks of age. Investigation into molecular mechanisms, revealed that EGCG down-regulated AR by 51%
in the VP, but not in the DLP. Down-regulated AR in the
VP may provide a means of protection in the prostate. It
is hypothesized that a reduction in AR decreases the
potential for testosterone and DHT to signal through
AR and cause prostate growth. In response, a plethora
of PCa treatments have been designed to target AR via
hormone therapy, including anti-androgens (i.e. bicaltumide, flutamide) and 5-a reductase inhibitors (i.e.,
Finasteride). Our findings support another study that
1586
Harper et al.
Fig. 6. COX-2 and iNOS protein expression inVP and DLP of12-week-old TRAMP mice fed AIN-76A diet and tap water (Control) or 0.06%
EGCG in tap water starting at 5 weeks of age.Upper bands depict western blots for COX-2 and iNOS and the lower figure is a graph of densitometry measurements from these western blot analyses. Each sample consisted of three pooled prostates and each group contained eight
samples.Densitometry values for controlmicewere set at100. *P < 0.05 and ***P < 0.001compared to control treatment.
showed the ability of EGCG to repress the transcription
of the AR gene in LNCaP PCa cells [18]. To our
knowledge, our study is the first to demonstrate AR
regulation in the prostate using EGCG in an in vivo
system. EGCG appears to regulate androgen action at
the receptor level, since there was no alteration in
testosterone and DHT in the blood. In addition, sex
steroid receptor, ER-a, and its natural ligand, estradiol,
was not modulated by EGCG and thus did not seem to
play a significant role in its mechanism of action. It is
well-known that estrogens play pivotal roles in normal
growth, development, and differentiation of the prostate [43], but their role in the PCa etiology is not
completely understood.
Not only was AR regulated in the prostate of
TRAMP mice by dietary EGCG, but so was the IGF-1
signaling pathway. EGCG regulated the IGF-1 signaling pathway at the ligand and receptor level. Our
results, demonstrated a decrease in IGF-1 in both
The Prostate DOI 10.1002/pros
prostate lobes with a concomitant decrease in the IGF1R in the VP. Adhami et al. showed decrease in IGF-1
and an increase in IGF-BP3 in the DLP and blood serum
of GTP-treated TRAMP mice [15]. Also, albeit in HT29
human colon cancer cells, a recent study described the
role of EGCG as a tyrosine receptor inhibitor via its
down-regulation of IGF-1R [44]. Although often
debated, elevated blood levels of IGF-1 has been
reported to be associated with an increased risk of
PCa [45,46]. Therefore, EGCG may act to slow the
progression of PCa by down-regulating IGF-1 signaling
in the prostate. Studies of IGF-1R expression in earlystage prostate tumors revealed elevated levels of IGF1R, while IGF-1R expression is reduced in advanced
and metastatic PCa [47]. The down-regulation of IGF1R expression in the VP of TRAMP mice at 12 weeks of
age by EGCG also suggests a chemoprevention action.
To investigate the effects of EGCG downstream of
AR and IGF-1 signaling, we measured phospho-ERKs
EGCG Suppresses HG-PIN
1 and 2, as well as proliferation and apoptosis. The sex
steroid receptor and transcription factor, AR, and
potent growth factor, IGF-1, can activate the MAPK
pathway which subsequently can lead to the transcription of genes responsible for cell proliferation and
apoptosis [48]. Cell proliferation and apoptosis are
important endpoints that are often measured to
determine if an agent is acting on the cell cycle to
inhibit or enhance cell growth and death. In addition,
agents that are able to attenuate MAPK, inhibit
proliferation, and induce apoptosis are often considered attractive candidates for cancer prevention and
therapy. In the current study, phospho-ERKs 1 and 2
were decreased in the VP of EGCG-treated mice. Our
finding compliments a previous study that showed an
inhibition of phospho-ERKs 1 and 2 in the DLP of GTPtreated TRAMP mice [15]. Phospho-ERKs 1 and 2 are
up-regulated in transgenic mice with PCa when
compared to their non-transgenic litermates [49]. Likewise, in our study, EGCG reduced cell proliferation by
54% and increased apoptosis by 394% in the VP of 12week TRAMP mice. The entire prostate, with the DLP
and VP measured as one entity, showed a similar but
less drastic reduction. In support of these results, an
array of in vitro studies has demonstrated a reduction
in cell proliferation and an increase in apoptosis in both
androgen-dependent and–independent PCa cell lines
[50–58].
It is plausible to postulate that cross-talk between AR
and the IGF-1 signaling pathway may have contributed
to and potentiated the effects observed in downstream
effectors, cell proliferation, and apoptosis. In LNCaP
cells, an AR positive PCa cell line, androgens upregulated IGF-1R expression and sensitized prostate
cells to the biological effects of IGF-1 [59]. Other studies
have provided evidence that IGF-1 and other growth
factors can activate AR in the presence [60] or absence
of androgens [17]. Therefore, a reduction in both AR
and IGF-1 in the prostate may create a microenvironment with reduced potential for PCa growth and
progression.
Because inflammation has been associated with PCa
progression, we investigated if EGCG could regulate
key proteins in this pathway. COX-2 and iNOS are two
important enzymes that mediate inflammatory processes, but can also produce reactive oxygen radicals
that can potentially damage DNA. COX-2 expression
has been reported to be over-expressed in prostate
adenocarcinoma [27], and excessive or aberrant iNOS
expression has been implicated in pathogenesis of
cancer [61]. Indeed, we showed a decrease in both COX2 and iNOS expression in the VP of EGCG-treated
animals. EGCG effectively reduced the potential for
DNA damage and cancer progression in the prostate by
inhibiting COX-2 and iNOS.
The Prostate DOI 10.1002/pros
1587
Our data illustrates a common theme in which
EGCG as a single agent acts in a lobe-specific fashion in
the rodent. EGCG reduced cell proliferation, induced
apoptosis, and modulated PCa biomarkers in the VP
only, with the exception of IGF-1 which was downregulated in both the DLP and VP. Our data, with
EGCG mediating most of its action via the VP, supports
other studies that have shown EGCG to protect against
PCa [34] and modulate inflammation and invasion of
PCa [21] in the VP only in TRAMP mice. In the TRAMP
model, the rapid and preferential development in the
DLP [22] may mask the anti-tumor (anti-cancer) effects
of EGCG on the VP at 28 weeks of age when evaluating
the prostate as a whole. Future studies are aimed at
evaluating the effects of EGCG at an intermediate age
(i.e., 17 weeks) to clarify this.
CONCLUSIONS
Any reduction in the carcinogenesis process by a
chemopreventive agent is a significant achievement
and has the potential to prolong the lifespan and
enhance the quality of life in men. EGCG as a single
agent inhibited HG-PIN, the precursor to PCa, but not
advanced, late-stage PCa in young adult TRAMP mice.
EGCG was able to change biomarkers that are
commonly associated with chemoprevention. Based
on our data, we suggest that the decrease in AR,
attenuation in the IGF-1 signaling pathway, reduction
in COX-2 and iNOS, and down-regulation of downstream effectors, phospho-ERKs 1 and 2 may contribute
to the reduction in cell proliferation and induction of
apoptosis and hence provide a mechanism of action for
EGCG suppressing PCa without toxicity.
ACKNOWLEDGMENTS
This research was supported by the Department of
Defense grant DOD DAMD PC 17-03-1-0153 to CAL.
CEH is supported by a National Cancer Institute
Cancer Prevention and Control Training Program
(NCI Grant CA 47888). We acknowledge Dr. Stephen
Barnes and UAB’s Mass Spectrometry facility, for
assistance in measuring polyphenol concentrations.
The facility is supported by NIH-P30 CA-13148-34. We
thank Dr. John Mahan, UAB OB/GYN, for blood serum
analysis of hormone concentrations and Dr. Mark
Carpenter, Auburn University, for his assistance with
statistical analysis.
REFERENCES
1. American Cancer Society. Cancer facts and figures. In: Society
AC, editor. ACS. Vol. 2006. Atlanta, GA: American Cancer
Society; 2006.
2. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The
frequency of carcinoma and intraepithelial neoplasia of the
prostate in young male patients. J Urol 1993;150(2 Pt 1):379–385.
1588
Harper et al.
3. Sakr WA, Ward C, Grignon DJ, Haas GP. Epidemiology and
molecular biology of early prostatic neoplasia. Mol Urol 2000;
4(3):109–113, discussion 115.
4. McNeal JE, Bostwick DG. Intraductal dysplasia: A premalignant
lesion of the prostate. Hum Pathol 1986;17(1):64–71.
5. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A.
Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade
prostate intraepithelial neoplasia: A preliminary report from a
one-year proof-of-principle study. Cancer Res 2006;66(2):1234–
1240.
6. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of
prostate carcinogenesis in TRAMP mice by oral infusion of green
tea polyphenols. Proc Natl Acad Sci USA 2001;98(18):10350–
10355.
7. Caporali A, Davalli P, Astancolle S, D’Arca D, Brausi M, Bettuzzi S,
Corti A. The chemopreventive action of catechins in the TRAMP
mouse model of prostate carcinogenesis is accompanied by
clusterin over-expression. Carcinogenesis 2004;25(11):2217–2224.
8. Saleem M, Adhami VM, Siddiqui IA, Mukhtar H. Tea beverage
in chemoprevention of prostate cancer: A mini-review. Nutr
Cancer 2003;47(1):13–23.
9. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea
against prostate cancer: A case-control study in southeast China.
Int J Cancer 2004;108(1):130–135.
10. Gronberg H. Prostate cancer epidemiology. Lancet 2003;
361(9360):859–864.
11. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N,
Nishino Y, Tsubono Y, Tsuji I. Green tea consumption and
mortality due to cardiovascular disease, cancer, and all causes in
Japan: The Ohsaki study. JAMA 2006;296(10):1255–1265.
12. Kikuchi N, Ohmori K, Shimazu T, Nakaya N, Kuriyama S,
Nishino Y, Tsubono Y, Tsuji I. No association between green tea
and prostate cancer risk in Japanese men: The Ohsaki Cohort
Study. Br J Cancer 2006;95(3):371–373.
13. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB.
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGFbinding protein-3, and prostate-specific antigen as predictors of
clinical prostate cancer. J Clin Endocrinol Metab 2000;85(11):
4258–4265.
14. Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum
insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to
risk of prostate cancer (United States). Cancer Causes Control
2003;14(8):721–726.
15. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral
consumption of green tea polyphenols inhibits insulin-like
growth factor-I-induced signaling in an autochthonous mouse
model of prostate cancer. Cancer Res 2004;64(23):8715–8722.
16. Liao S. The medicinal action of androgens and green tea
epigallocatechin gallate. Hong Kong Med J 2001;7(4):369–374.
17. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J,
Hittmair A, Bartsch G, Klocker H. Androgen receptor activation
in prostatic tumor cell lines by insulin-like growth factor-I,
keratinocyte growth factor, and epidermal growth factor. Cancer
Res 1994;54(20):5474–5478.
18. Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols
down-regulate the expression of the androgen receptor in LNCaP
prostate cancer cells. Oncogene 2000;19(15):1924–1932.
19. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems
and food intake by green tea epigallocatechin gallate. Endocrinology 2000;141(3):980–987.
The Prostate DOI 10.1002/pros
20. Sartor L, Pezzato E, Dona M, Dell’Aica I, Calabrese F, Morini M,
Albini A, Garbisa S. Prostate carcinoma and green tea: (-)
epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2
activation and invasion in murine TRAMP model. Int J Cancer
2004;112(5):823–829.
21. Tam NN, Nyska A, Maronpot RR, Kissling G, Lomnitski L, Suttie
A, Bakshi S, Bergman M, Grossman S, Ho SM. Differential
attenuation of oxidative/nitrosative injuries in early prostatic
neoplastic lesions in TRAMP mice by dietary antioxidants.
Prostate 2006;66(1):57–69.
22. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD,
Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM.
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA
1995;92(8):3439–3443.
23. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg
NM, Mukhtar H. Chemoprevention of prostate carcinogenesis
by alpha-difluoromethylornithine in TRAMP mice. Cancer Res
2000;60(18):5125–5133.
24. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken
JD, Barrios RS, Greenberg NM. E-7869, (R-flurbiprofen) inhibits
progression of prostate cancer in the TRAMP mouse. Cancer Res
2000;60(8):2203–2208.
25. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM,
Elgavish A. Genistein in the diet reduces the incidence of poorly
differentiated prostatic adenocarcinoma in transgenic mice
(TRAMP). Cancer Res 2001;61(18):6777–6782.
26. Lin X, Gingrich JR, Bao W, Li J, Haroon ZA, Demark-Wahnefried
W. Effect of flaxseed supplementation on prostatic carcinoma in
transgenic mice. Urology 2002;60(5):919–924.
27. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS,
Hafeli UO, Fu P, Mukhtar H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic
adenocarcinoma of the mouse prostate model. Cancer Res
2004;64(9):3334–3343.
28. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM,
Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R,
Ward JM, Cardiff RD. Prostate pathology of genetically
engineered mice: Definitions and classification. The consensus
report from the Bar Harbor meeting of the Mouse Models of
Human Cancer Consortium Prostate Pathology Committee.
Cancer Res 2004;64(6):2270–2305.
29. Wang ZY, Agarwal R, Bickers DR, Mukhtar H. Protection against
ultraviolet B radiation-induced photocarcinogenesis in hairless
mice by green tea polyphenols. Carcinogenesis 1991;12(8):1527–
1530.
30. Folkvord JM, Viders D, Coleman-Smith A, Clark RA. Optimization of immunohistochemical techniques to detect extracellular
matrix proteins in fixed skin specimens. J Histochem Cytochem
1989;37(1):105–113.
31. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT,
Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Human pathology
1994;25(8):797–801.
32. Drachenberg CB, Blanchaert R, Ioffe OB, Ord RA, Papadimitriou
JC. Comparative study of invasive squamous cell carcinoma and
verrucous carcinoma of the oral cavity: Expression of bcl-2, p53,
and Her-2/neu, and indexes of cell turnover. Cancer Detect Prev
1997;21(6):483–489.
33. Wheeler TM, Rogers E, Aihara M, Scardino PT, Thompson TC.
Apoptotic index as a biomarker in prostatic intraepithelial
neoplasia (PIN) and prostate cancer. J Cell Biochem 1994;19:202–
207.
EGCG Suppresses HG-PIN
34. Nyska A, Suttie A, Bakshi S, Lomnitski L, Grossman S, Bergman
M, Ben-Shaul V, Crocket P, Haseman JK, Moser G, Goldsworthy
TL, Maronpot RR. Slowing tumorigenic progression in TRAMP
mice and prostatic carcinoma cell lines using natural antioxidant from spinach, NAO—A comparative study of three antioxidants. Toxicol Pathol 2003;31(1):39–51.
35. Wang J, Eltoum IE, Lamartiniere CA. Genistein alters growth
factor signaling in transgenic prostate model (TRAMP). Mol Cell
Endocrinol 2004;219(1–2):171–180.
36. Crowther JR. The ELISA guidebook. Methods in molecular
biology (Clifton, NJ) 2000; 149: (III–IV), 1–413.
37. Coward L, Kirk M, Albin N, Barnes S. Analysis of plasma
isoflavones by reversed-phase HPLC-multiple reaction ion
monitoring-mass spectrometry. Clin Chim Acta Int J Clin Chem
1996;247(1–2):121–142.
38. Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary
genistein: Perinatal mammary cancer prevention, bioavailability
and toxicity testing in the rat. Carcinogenesis 1998;19(12):2151–
2158.
39. Wang J, Eltoum IE, Lamartiniere CA. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcin 2007;6:3.
1589
49. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression
and/or activation of P38MAPK, erk1/2, and jnk during the
initiation and progression of prostate cancer. Prostate 2003;55(2):
128–139.
50. Agarwal R. Cell signaling and regulators of cell cycle as
molecular targets for prostate cancer prevention by dietary
agents. Biochem Pharmacol 2000;60(8):1051–1059.
51. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H.
Green tea constituent epigallocatechin-3-gallate and induction
of apoptosis and cell cycle arrest in human carcinoma cells. J Natl
Cancer Inst 1997;89(24):1881–1886.
52. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY,
Kwok TT. Induction of apoptosis by green tea catechins in
human prostate cancer DU145 cells. Life Sci 2001;68(10):1207–
1214.
53. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth
inhibition, cell-cycle dysregulation, and induction of apoptosis
by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000;164(1):82–90.
40. Whitsett T, Carpenter M, Lamartiniere CA. Resveratrol, but not
EGCG, in the diet suppresses DMBA-induced mammary cancer
in rats. J Carcin 2006;5:15.
54. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys
2003;410(1):177–185.
41. Kim S, Lee MJ, Hong J, Li C, Smith TJ, Yang GY, Seril DN, Yang
CS. Plasma and tissue levels of tea catechins in rats and mice
during chronic consumption of green tea polyphenols. Nutr
Cancer 2000;37(1):41–48.
55. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML,
Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3gallate-induced apoptosis of LNCaP cells. Oncogene
2003;22(31):4851–4859.
42. Chen L, Lee MJ, Li H, Yang CS. Absorption, distribution,
elimination of tea polyphenols in rats. Drug Metab Dispos
1997;25(9):1045–1050.
43. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal
and abnormal development of the prostate gland. Ann N Y Acad
Sci 2006;1089:1–13.
44. Shimizu M, Deguchi A, Hara Y, Moriwaki H, Weinstein IB.
EGCG inhibits activation of the insulin-like growth factor-1
receptor in human colon cancer cells. Biochem Biophys Res
Commun 2005;334(3):947–953.
56. Paschka AG, Butler R, Young CY. Induction of apoptosis in
prostate cancer cell lines by the green tea component, (-)epigallocatechin-3-gallate. Cancer Lett 1998;130(1–2):1–7.
45. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J,
Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like
growth factor-I and prostate cancer risk: A prospective study.
Science 1998;279(5350):563–566.
46. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M,
Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF
binding protein-3 as predictors of advanced-stage prostate
cancer. J Natl Cancer Inst 2002;94(14):1099–1106.
47. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The
insulin-like growth factor axis and prostate cancer: Lessons from
the transgenic adenocarcinoma of mouse prostate (TRAMP)
model. Cancer Res 1999;59(9):2203–2209.
48. Nguyen TV, Yao M, Pike CJ. Androgens activate mitogenactivated protein kinase signaling: Role in neuroprotection.
J Neurochem 2005;94(6):1639–1651.
The Prostate DOI 10.1002/pros
57. Ravindranath MH, Saravanan TS, Monteclaro CC, Presser N, Ye
X, Selvan SR, Brosman S. Epicatechins purified from green tea
(Camellia sinensis) differentially suppress growth of genderdependent human cancer cell lines. Evid Based Complement
Alternat Med 2006;3(2):237–247.
58. Yu HN, Yin JJ, Shen SR. Growth inhibition of prostate cancer cells
by epigallocatechin gallate in the presence of Cu2þ. J Agric Food
Chem 2004;52(3):462–466.
59. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri
R, Belfiore A. Androgens up-regulate the insulin-like growth
factor-I receptor in prostate cancer cells. Cancer Res 2005;65(5):
1849–1857.
60. Orio F Jr, Terouanne B, Georget V, Lumbroso S, Avances C,
Siatka C, Sultan C. Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal
and cancer human prostate cell lines. Mol Cell Endocrinol
2002;198(1–2):105–114.
61. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS.
Molecular mechanisms underlying chemopreventive activities
of anti-inflammatory phytochemicals: Down-regulation of COX2 and iNOS through suppression of NF-kappa B activation.
Mutat Res 2001;480–481:243–268.